## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($48.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. C2C4C 2025 raises over $2M to advance cancer research**
- Source: Bristol Myers Squibb | 20251211T210813 | Bullish | Relevance: 99%
-  Bristol Myers Squibb's 12th annual C2C4C global bike ride event, involving over 300 employees from 33 nations, is projected to raise more than $2 million for cancer research charities. This brings the total raised by C2C4C rides to over $21 million in 12 years. The initiative demonstrates the company's commitment to transforming patients' lives through science, with participants including cancer survivors.

**2. Bristol Myers Squibb raises quarterly dividend by 1.6%**
- Source: Investing.com | 20251210T220228 | Bullish | Relevance: 99%
-  Bristol Myers Squibb (NYSE:BMY) has announced a 1.6% increase in its quarterly dividend, raising it to $0.63 per share. This marks the 17th consecutive year of dividend increases for the pharmaceutical company, which also maintains a "GREAT" financial health score and strong free cash flow. The company also declared a dividend for its convertible preferred stock.

**3. 66,361 Shares in Bristol Myers Squibb Company $BMY Bought by SVB Wealth LLC**
- Source: MarketBeat | 20251209T125009 | Somewhat-Bullish | Relevance: 99%
-  SVB Wealth LLC recently acquired 66,361 shares of Bristol Myers Squibb Company (NYSE:BMY), valued at approximately $3.07 million, contributing to institutional investors' 76.41% ownership of the company. Wall Street analysts currently hold a consensus "Hold" rating with an average target price of $55.25. The biopharmaceutical company reported strong Q3 earnings, beating expectations with $1.63 EPS and $12.22 billion in revenue, and announced a $2.48 annual dividend.

**4. U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for OpdivoÂ® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma**
- Source: Business Wire | 20251211T120135 | Bullish | Relevance: 99%
-  The U.S. Food and Drug Administration (FDA) has granted priority review to Bristol Myers Squibb's supplemental Biologics License Application (sBLA) for their drug Opdivo (nivolumab) in combination with chemotherapy for treating previously untreated Stage III or IV classical Hodgkin Lymphoma in adult and pediatric patients (12 years and older). This decision, based on the Phase 3 SWOG S1826 study, aims to provide a new first-line treatment option, with the FDA assigning a target action date of April 8, 2026. Bristol Myers Squibb believes this Opdivo combination could become a new standard of care, offering meaningful and durable outcomes for patients with this challenging disease.

**5. Jefferies Remains Bullish on Bristol-Myers Squibb Company (BMY)**
- Source: Insider Monkey | 20251210T112800 | Bullish | Relevance: 99%
-  Jefferies has reiterated a "Buy" rating on Bristol-Myers Squibb Company (BMY) with a price target of $68, following FDA approval for Breyanzi to treat relapsed or refractory marginal zone lymphoma. Scotiabank also raised its price target for BMY to $53, citing anticipated pivotal data readouts in 2026. Breyanzi is now the only FDA-approved CAR T cell therapy for five cancer types, showing strong efficacy and safety.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |
| 2025-12-02 | Goldman Sachs | $57 | $51 | +12% |
| 2025-11-17 | Citigroup | $45 | $48 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Perform |
| 2025-12-02 | Goldman Sachs | main | Neutral |
| 2025-11-17 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $104.2B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.6 |
| Current P/E | 7.8 |
| YoY Growth | -8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.9% to 0.7% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.3pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.69% (CS: 45) | Neutral |
| RSI_14 | 63.7 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.046x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $51.20
- **Stop Loss:** $48.66 (5.0% risk)
- **Target:** $53.74 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 543
- **Position Value:** $27,801.60
- **Portfolio %:** 27.80%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*